_id
691052c2ccc777a4e85d54e4
Ticker
COGT
Name
Cogent Biosciences Inc
Exchange
NASDAQ
Address
275 Wyman Street, Waltham, MA, United States, 02451
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.cogentbio.com
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Last Close
40.04
Volume
745695
Current Price
42.11
Change
5.1698301698301705
Last Updated
2025-11-29T11:43:56.757Z
Image
data:image/webp;base64,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
Ipo Date
2018-03-29T00:00:00.000Z
Market Cap
6173993984
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.8192142857142857
Sentiment Sources
14
Rating
4.1667
Target Price
47.1818
Strong Buy
5
Buy
4
Hold
3
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
83355000
Operating Income
-83355000
Interest Expense
1459000
Pretax Income
-80930000
Net Income
-80930000
Eps
-0.7070216783871693
Dividends Per Share
-
Shares Outstanding
153505562
Income Tax Expense
-
EBITDA
-78830000
Operating Margin
-
Total Other Income Expense Net
2425000
Cash
125297000
Short Term Investments
265593000
Receivables
-
Inventories
-
Total Current Assets
397244000
Property Plant Equipment
23865000
Total Assets
425933000
Payables
16029000
Short Term Debt
1706000
Long Term Debt
44250000
Total Liabilities
123469000
Equity
302464000
Depreciation
1147000
Change In Working Capital
4760000
Cash From Operations
-64286000
Capital Expenditures
65000
Cash From Investing
-155046000
Cash From Financing
217367000
Net Change In Cash
-2301000
PE
-
PB
15.936331691705458
ROE
-26.756903300888702
ROA
-19.000640945876466
FCF
-64351000
Fcf Percent
-
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
3
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
1
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
83355000
Quarters > 0 > income Statement > operating Income
-83355000
Quarters > 0 > income Statement > interest Expense
1459000
Quarters > 0 > income Statement > pretax Income
-80930000
Quarters > 0 > income Statement > net Income
-80930000
Quarters > 0 > income Statement > eps
-0.7070216783871693
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
114466080
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-78830000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
2425000
Quarters > 0 > balance Sheet > cash
125297000
Quarters > 0 > balance Sheet > short Term Investments
265593000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
397244000
Quarters > 0 > balance Sheet > property Plant Equipment
23865000
Quarters > 0 > balance Sheet > total Assets
425933000
Quarters > 0 > balance Sheet > payables
16029000
Quarters > 0 > balance Sheet > short Term Debt
1706000
Quarters > 0 > balance Sheet > long Term Debt
44250000
Quarters > 0 > balance Sheet > total Liabilities
123469000
Quarters > 0 > balance Sheet > equity
302464000
Quarters > 0 > cash Flow > net Income
-80930000
Quarters > 0 > cash Flow > depreciation
1147000
Quarters > 0 > cash Flow > change In Working Capital
4760000
Quarters > 0 > cash Flow > cash From Operations
-64286000
Quarters > 0 > cash Flow > capital Expenditures
65000
Quarters > 0 > cash Flow > cash From Investing
-155046000
Quarters > 0 > cash Flow > cash From Financing
217367000
Quarters > 0 > cash Flow > net Change In Cash
-2301000
Quarters > 0 > ratios > PE
-0.7070216783871693
Quarters > 0 > ratios > PB
15.936331691705458
Quarters > 0 > ratios > ROE
-26.756903300888702
Quarters > 0 > ratios > ROA
-19.000640945876466
Quarters > 0 > ratios > FCF
-64351000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
1157000
Quarters > 1 > income Statement > gross Profit
-1157000
Quarters > 1 > income Statement > operating Expenses
74425000
Quarters > 1 > income Statement > operating Income
-75582000
Quarters > 1 > income Statement > interest Expense
314000
Quarters > 1 > income Statement > pretax Income
-73529000
Quarters > 1 > income Statement > net Income
-73529000
Quarters > 1 > income Statement > eps
-0.6423649696049695
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
114466080
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-72058000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
2053000
Quarters > 1 > balance Sheet > cash
127598000
Quarters > 1 > balance Sheet > short Term Investments
110250000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
245008000
Quarters > 1 > balance Sheet > property Plant Equipment
24947000
Quarters > 1 > balance Sheet > total Assets
274817000
Quarters > 1 > balance Sheet > payables
16625000
Quarters > 1 > balance Sheet > short Term Debt
1658000
Quarters > 1 > balance Sheet > long Term Debt
43949000
Quarters > 1 > balance Sheet > total Liabilities
119781000
Quarters > 1 > balance Sheet > equity
155036000
Quarters > 1 > cash Flow > net Income
-73529000
Quarters > 1 > cash Flow > depreciation
1157000
Quarters > 1 > cash Flow > change In Working Capital
7835000
Quarters > 1 > cash Flow > cash From Operations
-54542000
Quarters > 1 > cash Flow > capital Expenditures
131000
Quarters > 1 > cash Flow > cash From Investing
8910000
Quarters > 1 > cash Flow > cash From Financing
47227000
Quarters > 1 > cash Flow > net Change In Cash
1595000
Quarters > 1 > ratios > PE
-0.6423649696049695
Quarters > 1 > ratios > PB
31.090628168941404
Quarters > 1 > ratios > ROE
-47.42704920147578
Quarters > 1 > ratios > ROA
-26.755622832648633
Quarters > 1 > ratios > FCF
-54673000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
1138000
Quarters > 2 > income Statement > gross Profit
-1138000
Quarters > 2 > income Statement > operating Expenses
74933000
Quarters > 2 > income Statement > operating Income
-74933000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-71986000
Quarters > 2 > income Statement > net Income
-71986000
Quarters > 2 > income Statement > eps
-0.6353129357042411
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
113307940
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-73795000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2947000
Quarters > 2 > balance Sheet > cash
126003000
Quarters > 2 > balance Sheet > short Term Investments
119658000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
252884000
Quarters > 2 > balance Sheet > property Plant Equipment
26052000
Quarters > 2 > balance Sheet > total Assets
283798000
Quarters > 2 > balance Sheet > payables
14154000
Quarters > 2 > balance Sheet > short Term Debt
1611000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
64803000
Quarters > 2 > balance Sheet > equity
218995000
Quarters > 2 > cash Flow > net Income
-71986000
Quarters > 2 > cash Flow > depreciation
1138000
Quarters > 2 > cash Flow > change In Working Capital
-4716000
Quarters > 2 > cash Flow > cash From Operations
-66511000
Quarters > 2 > cash Flow > capital Expenditures
547000
Quarters > 2 > cash Flow > cash From Investing
69379000
Quarters > 2 > cash Flow > cash From Financing
24970000
Quarters > 2 > cash Flow > net Change In Cash
27838000
Quarters > 2 > ratios > PE
-0.6353129357042411
Quarters > 2 > ratios > PB
21.787699963012855
Quarters > 2 > ratios > ROE
-32.87107011575607
Quarters > 2 > ratios > ROA
-25.365224561131512
Quarters > 2 > ratios > FCF
-67058000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
4292000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
2146000
Quarters > 3 > income Statement > operating Expenses
73734000
Quarters > 3 > income Statement > operating Income
-73734000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-67927000
Quarters > 3 > income Statement > net Income
-67927000
Quarters > 3 > income Statement > eps
-0.6149369615606868
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
110461729
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-72626000
Quarters > 3 > income Statement > operating Margin
-1717.9403541472507
Quarters > 3 > income Statement > total Other Income Expense Net
5807000
Quarters > 3 > balance Sheet > cash
98165000
Quarters > 3 > balance Sheet > short Term Investments
188912000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
296472000
Quarters > 3 > balance Sheet > property Plant Equipment
26564000
Quarters > 3 > balance Sheet > total Assets
327898000
Quarters > 3 > balance Sheet > payables
12013000
Quarters > 3 > balance Sheet > short Term Debt
1565000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
71612000
Quarters > 3 > balance Sheet > equity
256286000
Quarters > 3 > cash Flow > net Income
-67927000
Quarters > 3 > cash Flow > depreciation
1158000
Quarters > 3 > cash Flow > change In Working Capital
-1131000
Quarters > 3 > cash Flow > cash From Operations
-60577000
Quarters > 3 > cash Flow > capital Expenditures
75000
Quarters > 3 > cash Flow > cash From Investing
61671000
Quarters > 3 > cash Flow > cash From Financing
26000
Quarters > 3 > cash Flow > net Change In Cash
1120000
Quarters > 3 > ratios > PE
-0.6149369615606868
Quarters > 3 > ratios > PB
18.14981469214081
Quarters > 3 > ratios > ROE
-26.504374019649923
Quarters > 3 > ratios > ROA
-20.715893357080557
Quarters > 3 > ratios > FCF
-60652000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-14.131407269338304
Quarters > 3 > health Score
27
Valuation > metrics > PE
-0.7070216783871693
Valuation > metrics > PB
15.936331691705458
Valuation > final Score
20
Valuation > verdict
431.2% Overvalued
Profitability > metrics > ROE
-26.756903300888702
Profitability > metrics > ROA
-20.372869067877676
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.4082105639018197
Risk > metrics > Interest Coverage
-57.13159698423578
Risk > final Score
-169
Risk > verdict
High
Liquidity > metrics > Current Ratio
22.398872286439243
Liquidity > metrics > Quick Ratio
22.398872286439243
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-915
Prev Risks > 1
-106
Prev Risks > 2
-3
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:21:23.763Z
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACogent Biosciences Stock Surged by Positive Pivotal Trial Results StocksToTrade
Read more →Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
12/14/2025
Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$47.1818
Analyst Picks
Strong Buy
5
Buy
4
Hold
3
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 97.30% of the total shares of Cogent Biosciences Inc
1.
FMR Inc(12.225%)
since
2025/06/30
2.
Paradigm Biocapital Advisors LP(7.4104%)
since
2025/06/30
3.
BlackRock Inc(6.175%)
since
2025/06/30
4.
Kynam Capital Management, LP(6.0791%)
since
2025/06/30
5.
TCG Crossover Management, LLC(4.9852%)
since
2025/06/30
6.
Vanguard Group Inc(4.6692%)
since
2025/06/30
7.
Fairmount Funds Management LLC(4.4564%)
since
2025/06/30
8.
Point72 Asset Management, L.P.(3.516%)
since
2025/06/30
9.
VR Adviser, LLC(3.404%)
since
2025/06/30
10.
Vanguard Total Stock Mkt Idx Inv(2.9093%)
since
2025/07/31
11.
UBS Group AG(2.5187%)
since
2025/06/30
12.
Fidelity Select Health Care(2.4195%)
since
2025/07/31
13.
State Street Corp(2.4137%)
since
2025/06/30
14.
Vestal Point Capital LP(2.2047%)
since
2025/06/30
15.
HHG PLC(2.0566%)
since
2025/06/30
16.
Octagon Capital Advisors LP(1.9778%)
since
2025/06/30
17.
Geode Capital Management, LLC(1.9127%)
since
2025/06/30
18.
Deerfield Management Co(1.8899%)
since
2025/06/30
19.
Fidelity Advisor Biotechnology I(1.8459%)
since
2025/07/31
20.
Fidelity Small Cap Growth(1.8419%)
since
2025/06/30
21.
iShares Russell 2000 ETF(1.8404%)
since
2025/08/31
22.
Sofinnova Ventures(1.6861%)
since
2025/06/30
23.
COMMODORE CAPITAL LP(1.6544%)
since
2025/06/30
24.
Saturn V Capital Management LLC(1.6446%)
since
2025/06/30
25.
Fidelity Advisor Health Care I(1.36%)
since
2025/07/31
26.
FIAM Small Cap Core Composite(1.3363%)
since
2025/03/31
27.
Nantahala Capital Management, LLC(1.1852%)
since
2025/06/30
28.
Fidelity Select Biotechnology(1.1214%)
since
2025/07/31
29.
Vanguard Institutional Extnd Mkt Idx Tr(0.9914%)
since
2025/07/31
30.
Fidelity Stock Selector Small Cap(0.9168%)
since
2025/06/30
31.
Strategic Advisers Fidelity US TtlStk(0.8447%)
since
2025/07/31
32.
Fidelity Small Cap Growth K6(0.8282%)
since
2025/06/30
33.
Fidelity Series Small Cap Opps(0.809%)
since
2025/06/30
34.
SPDR® S&P Biotech ETF(0.7994%)
since
2025/08/31
35.
Fidelity Small Cap Index(0.7629%)
since
2025/06/30
36.
iShares Russell 2000 Growth ETF(0.6303%)
since
2025/08/31
37.
Belfius Equities Cure C Cap(0.5528%)
since
2025/08/31
38.
Fidelity Extended Market Index(0.5017%)
since
2025/07/31
39.
iShares Biotechnology ETF(0.4806%)
since
2025/08/31
40.
Schwab US Small-Cap ETFâ„¢(0.4413%)
since
2025/08/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.